☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Kite's Tecartus Receives the US FDA's Approval as the First and Only Car T for Adults with Relapsed or Refractory B-cell Acute Lym...
October 4, 2021
Amgen and Astellas' Blincyto (blinatumomab- BiTE) Receives Japanese Marketing Approval for Treatment of R/R B-cell Acute Lymphobla...
September 25, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.